Anti-Interferon gamma antibody (ab9657)
- Product nameAnti-Interferon gamma antibodySee all Interferon gamma primary antibodies ...
- DescriptionRabbit polyclonal to Interferon gamma
- Tested applicationsWB, ELISA, Neutralising, ICC/IF, IHC-P more details
- Species reactivityReacts with: Human
Highly pure (>98%) recombinant hIFN-gamma (human Interferon-gamma).
- FormLyophilised:Reconstitute with 200µl of sterile water.
- Storage instructionsStore at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze / thaw cycles.
- Storage bufferPBS, pH 7.4, no preservative, sterile filtered
- Concentration information loading...
- PurityImmunogen affinity purified
- Clonality Polyclonal
- Light chain typeunknown
- Research Areas
Our Abpromise guarantee covers the use of ab9657 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||WB: Use at an assay dependent concentration. To detect hIFN-gamma by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIFN-gamma is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.|
|ELISA||ELISA: Use at an assay dependent concentration. Can be paired for ELISA with Mouse monoclonal to Interferon gamma (ab9658). To detect hIFN-gamma by direct ELISA (using 100µl/well antibody solution) a concentration of at least 0.5µg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2 - 0.4 ng/well of recombinant hIFN-gamma.|
|Neutralising||Neut: Use at an assay dependent concentration. To yield one-half maximal inhibition [ND50] of the biological activity of hIFN-gamma (50 pg/ml), a concentration of 0.04 - 0.06 ng/ml of this antibody is required.|
|ICC/IF||ICC/IF: Use at an assay dependent concentration.|
|IHC-P||IHC-P: Use a concentration of 0.25 - 0.5 µg/ml.|
- FunctionProduced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.
- Tissue specificityReleased primarily from activated T lymphocytes.
- Involvement in diseaseIn Caucasians, genetic variation in IFNG is associated with the risk of aplastic anemia (AA) [MIM:609135]. AA is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis.
- Sequence similaritiesBelongs to the type II (or gamma) interferon family.
modificationsProteolytic processing produces C-terminal heterogeneity, with proteins ending alternatively at Gly-150, Met-157 or Gly-161.
- Cellular localizationSecreted.
- IFG antibodyIFI antibodyIFN Gamma antibody
- IFN Immune antibodyIFN-gamma antibodyIFNG antibodyIFNG antibodyIFNG_HUMAN antibodyImmune Interferon antibodyInterferon gamma antibodyInterferon Gamma Precursor antibodyMacrophage Activating Factor antibodyMAF antibodyT Cell Interferon antibodyType II Interferon antibody
Anti-Interferon gamma antibody images
ab9657 staining Interferon gamma in human cervical squamous cell carcinoma section by Immunohistochemistry (Formalin/PFA fixed paraffin-embedded sections). Tissue underwent heat mediated antigen retrieval in sodium citrate buffer (pH 6.0). The primary antibody was used at 0.25 ug/ml and incubated with sample at 4°C overnight. A HRP-labeled polymer detection system was used with a DAB chromogen
References for Anti-Interferon gamma antibody (ab9657)
This product has been referenced in:
- Tanaka A et al. Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease. Arthritis Rheum 64:254-63 (2012). IHC-P ; Human . Read more (PubMed: 21898360) »
- Belogurov AA et al. Liposome-encapsulated peptides protect against experimental allergic encephalitis. FASEB J : (2012). IHC . Read more (PubMed: 23047895) »